dc-cik细胞免疫疗法治疗非小细胞肺癌（nsclc）的临床疗效评价

《dc-cik细胞免疫疗法治疗非小细胞肺癌（nsclc）的临床疗效评价》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号16189中国图书分类号R730.54HebeiMedicalUniversity硕士学位论文学术学位DC-CIK细胞免疫疗法治疗非小细胞肺癌（NSCLC）的临床疗效评价研究生：宫敬伟导师：曾瑞红教授专业：免疫学二级学院：基础医学院2018年3月11目录中文摘要································································································1英文摘要·························

2、················································································3英文缩写············································································································5研究论文DC-CIK细胞免疫疗法治疗非小细胞肺癌（NSCLC）的临床疗效评价前言········································

3、················································6材料与方法························································································8结果······························································································12附图·······························

4、·······································································14附表·································································································16讨论··································································································

5、····18结论··························································································22参考文献····························································································22综述DC-CIK细胞免疫疗法治疗非小细胞肺癌(NSCLC)的临床应用进展········································

6、·····························································25致谢··················································································································36个人简历·························································································

7、·················37DC-CIK细胞免疫疗法治疗非小细胞肺癌（NSCLC）的临床疗效评价摘要目的：采集自体外周血单个核细胞（Peripheralbloodmononuclearcell,PBMC），经体外分离、诱导培养制备树突状细胞（Dendriticcells，DC）与细胞因子诱导的杀伤细胞(Cytokineinducedkiller,CIK)，然后混合培养诱导制备CTL细胞（CytotoxicTlymphocyte,CTL），探讨利用DC-CIK-CTL细胞免疫治疗晚期非小细胞肺癌(non-smallcelllungca

8、ncer,NSCLC)的临床疗效。传统的放化疗手段对恶性肿瘤呈指数性杀伤，但尚需借助机体自身免疫机能来对恶性肿瘤综合疗法实施后残留的微小病变施以抑制和清除。生物免疫